Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Suppression of multiple mouse models of refractory malignancies by reprogramming IL-18 ligand-receptor interaction

3 Jul 2025

Abstract excerpt

Achieving a cure is an urgent need for patients with advanced solid tumors. Here, we discover that oncolytic virus (OV) infection enhances IL-18 receptor expression but fails to increase IL-18 ligand expression. Therefore, we engineer armed oncolytic alphavirus M1 expressing wild-type IL-18 (wtIL-18) or a mutant variant (mutIL-18) that evades IL-18 binding protein (IL-18BP) while maintaining IL-18 receptor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40610476
DOI: 10.1038/s41467-025-61439-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Suppression of multiple mouse models of refractory malignancies by reprogramming IL-18 ligand-receptor interactionPMID 40610476Read ↗

Interleukin-18 (IL-18) engineered for half-life extension and resistance to IL-18 binding protein (IL-18BP) to enhance anti-cancer therapeutic potentialSemantic proximity Read ↗

The oncolytic virus ΔPK has multimodal anti-tumor activity.Semantic proximity Read ↗

Immune modulation of innate and adaptive responses restores immune surveillance and establishes anti-tumor immunological memorySemantic proximity Read ↗

Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus.Semantic proximity Read ↗

Adaptive anti-tumor immunity is orchestrated by a population of CCL5-producing tissue-resident NK cellsSemantic proximity Read ↗

Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors.Semantic proximity Read ↗

Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancerSemantic proximity Read ↗

An autologous cell-based therapeutic vaccine expressing IL6/1 fusokine drives robust anti-tumor response against ovarian cancerSemantic proximity Read ↗

The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8 <sup>+</sup> T cell activity and synergizes with immune check-point inhibitorsSemantic proximity Read ↗

Elucidating Mechanisms of Antitumor Immunity Mediated by Live Oncolytic Vaccinia and Heat-Inactivated VacciniaSemantic proximity Read ↗

<i>First-in-class</i> Transactivator-Free, Doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B-cell lymphomasSemantic proximity Read ↗

Deletion of immune evasion genes provides an effective vaccine design for tumor-associated herpesvirusesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.